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concept of risk factors for coro- nary heart disease (CHD) and has served as the stan- dard 
for risk assessment over the years.1-4 Major risk factors identified by the Framingham Heart 
Study, in- cluding age, sex, total cholesterol, high-density li- poprotein (HDL) cholesterol, 
smoking, and systolic blood pressure, have been incorporated into a scoring system that 
identifies subjects at high (>20%), interme- diate (10%–20%), and low (<10%) risk for 
developing CHD over the next 10 years.5 These major or tradi- tional risk factors account 
for approximately 50% of the variability in risk in high-risk populations and ex- plain >80% 
of the excess population risk for CHD.6-8 Recent clinical trials in high-risk subjects 
demonstrate dramatic reductions in risk (approximately 33%–50% in 5 y) with risk 
reduction therapies.9  This provides strong support for the concept that CHD and its se- 
quela can be prevented by aggressive medical therapy and therapeutic lifestyle changes. 
Recent American Heart Association (AHA) guidelines (2002)4 for primary prevention of 
cardiovascular disease and stroke recom- mend that risk-factor screening in adults should 
begin at age 20 and should be repeated at least every 5 years in the absence of risk factors and 
every 2 years if risk factors are present. This panel recommends that global risk should be 
estimated in all adults >40 years of age. In this issue of the Journal, Cohn et al10 have pro-
posed a method for risk assessment that focuses on measurements of early vascular 
dysfunction and dis- ease markers rather than standard risk factors. Studies are ongoing in 
their outpatient cardiovascular disease prevention clinic to validate the model by relating 
risk assessments to disease outcomes over time.
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Assessing risk for coronary heart disease: Beyond 
Framingham 
Frederick R. Cobb, William E. Kraus, Martin Root, and Jason D. Allen 
The Framingham Heart Study, initiated over 50 years 
ago, introduced the concept of risk factors for coro- 
nary heart disease (CHD) and has served as the stan- 
dard for risk assessment over the years.1-4 Major risk 
factors identified by the Framingham Heart Study, in- 
cluding age, sex, total cholesterol, high-density li- 
poprotein (HDL) cholesterol, smoking, and systolic 
blood pressure, have been incorporated into a scoring 
system that identifies subjects at high (>20%), interme- 
diate (10%–20%), and low (<10%) risk for developing
CHD over the next 10 years.5 These major or tradi- 
tional risk factors account for approximately 50% of 
the variability in risk in high-risk populations and ex- 
plain >80% of the excess population risk for CHD.6-8
Recent clinical trials in high-risk subjects demonstrate 
dramatic reductions in risk (approximately 33%–50% in 
5 y) with risk reduction therapies.9  This provides 
strong support for the concept that CHD and its se- 
quela can be prevented by aggressive medical therapy 
and therapeutic lifestyle changes. Recent American 
Heart Association (AHA) guidelines (2002)4 for primary 
prevention of cardiovascular disease and stroke recom- 
mend that risk-factor screening in adults should begin 
at age 20 and should be repeated at least every 5 years 
in the absence of risk factors and every 2 years if risk 
factors are present. This panel recommends that global 
risk should be estimated in all adults >40 years of age.
In this issue of the Journal, Cohn et al10 have pro- 
posed a method for risk assessment that focuses on 
measurements of early vascular dysfunction and dis- 
ease markers rather than standard risk factors. Studies 
are ongoing in their outpatient cardiovascular disease 
prevention clinic to validate the model by relating risk 
assessments to disease outcomes over time. 
A guiding principle of primary prevention therapy is 
that the intensity of risk reduction therapies should be 
tailored to the level of individual risk.2,3,6,9  Although 
the AHA/ACC Scientific Statement on assessment of 
cardiovascular risk,9 the AHA sponsored Prevention 
Conference V,6 and the National Cholesterol Education 
Program (NCEP), Adult Treatment Panel III (ATP III)3
recommend risk factor assessment and Framingham 
score as first steps to guide therapeutic strategies, each 
panel recognized that factors other than the traditional 
Framingham risk factors contribute significantly to 
global risk for CHD. Table I lists the traditional Fra- 
mingham risk factors and additional potential catego- 
ries that may contribute to risk. The list is a modifica- 
tion of categories described by the AHA/ACC Scientific 
Statement9 and Prevention Conference V.6 The follow- 
ing discussion provides (1) an overview of these non- 
Framingham risk categories, (2) a potential algorithm 
for incorporating parameters from these risk categories 
into risk assessment beyond that provided by a Fra- 
mingham score, and (3) a potential approach to esti- 
mating global absolute risk based on analyses that 
combines Framingham risk factor and risk variables 
from multiple data sets. 
Coronary disease equivalents 
Subjects with diagnosed CHD have a >20% 10-year
risk for developing future cardiac events including 
acute myocardial infarction and cardiac death and thus 
are at high risk. Noncardiac conditions with similar 
risk are referred to as coronary disease equivalents. 
The Prevention Conference V6 and ATP III3 recognized 
that patients with diabetes mellitus, symptomatic ca- 
rotid artery disease, and peripheral vascular disease 
have a >20% 10-year risk for developing cardiac
events, placing them in the high-risk population and 
requiring aggressive risk-factor reduction through med 
ical therapies and therapeutic lifestyle changes. 
Predisposing risk factors 
Predisposing risk factors for coronary heart disease, 
defined as those that worsen independent risk fac 
tors,6,9 include (1) family history of premature CHD, 
occurring in a first degree male relative <55 years of
age, or first degree female relative, <65 years of age,
(2) metabolic or insulin resistance syndrome (defined 
as >3 of the following: abdominal obesity [male >102
cm waist, female > 88 cm], fasting glucose >110 mg/
dL, systolic pressure >130 mm Hg, diastolic >85 mm
Hg, triglycerides >150 mg/dL, HDL cholesterol <40
mg/dL in males and <50 mg/dL in females), (3) obe
sity (body mass index >30 kg/m2) and, (4) physical
inactivity. Obesity and physical inactivity are consid 
ered major risk factors by the AHA.11,12 ATP III3 recog 
nized metabolic syndrome as a secondary target for 
risk reduction therapy after the primary target, low- 
density lipoprotein (LDL) cholesterol. Significant de 
pression also has been recognized to be associated 
with increased coronary heart disease events.13
Conditional or emerging risk factors 
Conditional risk factors are defined as those associ 
ated with increased risk for CHD but whose causative, 
independent, and quantitative contribution to CHD 
need additional documentation.6,9  These include the 
inflammatory marker, high sensitivity C-reactive pro 
tein (hs-CRP),14,15  homocysteine, lipoprotein(a), small 
dense LDL particles, which appear to be atherogenic, 
and prothrombotic factors (ie, plasminogen activator 
inhibitor [PAI-1] and fibrinogen). These parameters 
have been identified in certain studies to provide a 
graded independent risk for developing coronary heart 
disease.16,20  With time, one or more may be accepted 
not only as a major risk factor but also a target for 
therapy. For example, a recent panel convened by the 
AHA and Center for Disease Control and Prevention21
reviewed the data relating hs-CRP to risk for CHD, sud 
den death, and preclinical vascular disease. An hs-CRP 
level of 1 to 3.0 mg/L was associated with an average 
risk, whereas a level >3.0 mg/L was associated with a
>2 relative risk or high risk. They recommended lim
ited use of hs-CRP as an independent marker for fur 
ther risk stratification in people at intermediate risk. 
ATP III noted that although the emerging risk factors 
should not be used to modify LDL cholesterol goals, 
they may be used to guide intensity of risk reduction 
therapy. 
Assessment of atherosclerotic plaque 
burden: preclinical vascular disease 
Current thinking about the pathogenesis of coronary 
heart disease15,22  holds that atherosclerosis begins in 
early adult life when LDL particles from the circulating 
blood become attached to the arterial endothelial layer 
and migrate to the intima, where they become trapped 
in macrophages to form foam cells. As the foam cells 
accumulate, they form fatty streaks on the vessel lin- 
ing. The fatty streaks gradually enlarge to form raised 
fibrous plaques. The fibrous plaques contain a variety 
Framingham risk factors 
Age 
Total cholesterol (LDL cholesterol) 
Smoking 
HDL cholesterol 
Systolic blood pressure 
LVH 
Coronary  disease  equivalents 
Diabetes mellitus 
Symptomatic carotid disease 
Peripheral  vascular  disease 
Predisposing risk factor 
Family history of premature coronary heart disease 
Metabolic syndrome—insulin resistance 
Obesity 
Physical inactivity 
Psychosocial factors 
Ethnic characteristics 
Conditional risk factors 
Inflammatory markers (ie, elevated hs-CRP) 
Increased homocysteine 
Increased lipoprotein (a) Increased 
small dense LDL particle 
Increased prothrombotic factors, ie, fibrinogen PAI-1 
Noninvasive assessment of atherosclerotic plaque burden and/or 
preclinical vascular disease  
Ankle/brachial blood pressure index (ABI) 
Coronary calcium score—EBCT, helical CT 
Carotid intima media thickening (CIMT), B-mode Echo 
Endothelial function-brachial artery flow mediated dilation (BAFMD) 
Plaque characterization-MRI, CT 
Arterial elasticity (compliance) 
Micro  albuminuria 
Assessment of silent ischemia 
Exercise  ECG  testing 
Exercise and pharmacologic stress echo 
Exercise and pharmacologic perfusion imaging 
of inflammatory cells and subsequently develop a fi- 
brous cap and a central lipid core. Calcium becomes 
deposited in the core of the plaque. Influenced by 
multiple risk factors, the process of plaque develop- 
ment and growth progresses at a variable rate over 
years. When certain plaques narrow the artery approx 
imately >75%, pain symptoms may occur during physi 
cal activities, and exercise stress test may become pos 
itive. It is thus apparent that symptoms first occur at a 
late stage when the disease is far advanced, often in 
volving not only multiple coronary arteries but also 
multiple organ systems. Cardiac events including unsta 
ble angina, acute myocardial infarction, and sudden 
death may occur earlier without warning due to rup 
ture of the fibrous cap resulting in acute thrombosis 
and interruption of blood flow. Studies have demon 
strated that plaque rupture, in many cases, occurs  
from plaques that are not severe enough to limit blood 
flow or cause symptoms or abnormal functional test.23
The atherosclerotic process is thus present and ac 
Table I. Risk factor categories for coronary heart disease 
tively progressing many years before symptoms, acute 
cardiac events, and exercise or stress-inducible isch- 
emia. It is also apparent that measurements of the 
presence and activity of the preclinical atherosclerotic 
process, representing the vascular expression of multi 
ple interacting risk factors, is essential to not only en- 
hance risk assessment,24  but may also provide new 
patients who are at intermediate risk. A low score may 
be used to place the patient in a lower risk category. 
A higher score (ie, greater than the 75th percentile for 
age) may place the patient in a higher risk group. 
Carotid intima-medial thickening 
24 
targets for risk reduction therapy. Endothelial dysfunc- Prevention Conference V, 2000, summarized the 
tion, a potential measure of disease activity, is present 
very early in the atherosclerotic process,25-28  even in 
arteries that do not demonstrate significant plaque de 
velopment. A variety of new technologies are now 
available to assess preclinical vascular disease, athero 
role of B-mode ultrasound measurements of carotid 
intima-media thickening (IMT) in assessing CHD risk. 
The panel noted that carotid IMT was related to car- 
diovascular risk factors and was an independent pre 
dictor of atherosclerosis and CHD events and 
sclerotic plaque burdens, and endothelial function be- stroke.
39-41
 In the Cardiovascular Health Study41 that 
fore the onset of symptoms.24 The following provides 
an overview of these technologies. 
Ankle/brachial blood pressure index (ABI) 
The ABI measurement requires only a blood pressure 
cuff and hand held Doppler, and thus is a very simple 
and inexpensive office-based diagnostic test for periph- 
eral arterial disease of the lower extremities. An ABI 
:S0.90 in 1 leg confirms the diagnosis of preclinical 
vascular disease and has an approximately 90% sensi- 
tivity and 95% specificity for >50% stenosis in the
lower   extremities.29,30
Coronary calcification score 
The amount of calcium localized in the atheroscle- 
rotic plaques within the coronary arteries can be quan- 
titated with electronic beam computed tomography 
(EBCT) or helical computed tomography.31-33 Although 
the calcium score provides an index of plaque bur 
den,33 it does not define severity of stenosis or identify 
unstable plaques. Certain studies support the indepen 
dent prognostic value of the coronary calcification 
score (CCS).34-36  Other studies have reported that the 
CCS does not provide risk assessment beyond that pro 
vided by Framingham risk factor analysis.37 Because 
CCS increases progressively with age and is influenced 
by sex, the CCS should be interpreted as a function of 
age and sex. A CCS in the 75th percentile for age or 
greater indicates excess plaque formation and in 
creased risk for future events. Grundy et al38 has sug 
gested that the CCS as a measure of plaque burden 
may be considered as a substitute for age as a risk fac 
tor in the Framingham risk equation. Because coronary 
calcifications tend to lag behind plaque formation, the 
presence of a low CCS in subjects with significant risk 
factors should not be used to exclude therapy, espe 
cially at an early age. Although CCS is currently being 
used throughout the United States to assess asymptom 
atic atherosclerosis and risk, Prevention Conference V 
2000,24  convened in 1998, felt that its greatest poten 
tial was in the detection of advanced atherosclerosis in 
included patients >65 years of age without clinical
CHD, the relative risk for MI or stroke increased lin 
early with IMT, with a relative risk in the highest ver 
sus lowest quintile of 3.87. The association was signifi 
cant after adjustment for traditional risk factors. The 
panel concluded that in asymptomatic subjects >45
years of age, carotid IMT measurements in an experi 
enced laboratory provide incremental information to 
traditional risk factor assessment. Serial measurements 
of carotid IMT may provide a measure of disease pro 
gression and thus an additional way to monitor. 
Endothelial function: Brachial artery flow mediated 
dilation 
Through its unique location and functions, the endo 
thelium plays a key role in the development of athero 
sclerosis and its thrombotic consequences. A healthy 
endothelium produces a variety of anti-atherogenic 
substances, including nitric oxide, which promotes 
vasodilation in addition to its multiple anti-atherogenic 
properties, which include inhibition of monocyte, leu 
kocyte, and platelet adhesion to the vessel wall, inhibi 
tion of platelet aggregation, antioxidant properties and 
inhibition of smooth muscle proliferation.42 Studies 
have demonstrated that endothelial mediated vasodila 
tion is reduced early in the atherosclerotic process, 
even before angiographic morphologic changes.25,26  It 
is also reduced in animal models and patients with hy 
percholesterolemia before the appearance of athero 
sclerosis,27,28  and progressively worsens as the severity 
of atherosclerosis increases.43,44  An increase in blood 
flow increases shear stress and stimulates release of 
nitric oxide by a healthy endothelium resulting in ves 
sel dilation. This physiologic observation and the close 
association between vasoreactivity in the brachial and 
coronary arteries45  has led to widespread use of bra 
chial artery vasoreactivity to evaluate endothelial func 
tion. This technique involves a 5minute forearm cuff 
occlusion and subsequent release to produce a reac 
tive hyperemic increase in blood flow, and high-resolu 
tion ultrasound to quantitate changes in brachial artery 
diameter (BAFMD). Most of the Framingham risk fac 
tors and many of the emerging risk factors are associ 
ated with endothelial dysfunction.4652 Risk factor mod 
ification may improve endothelial function and 
BAFMD.52-55 More importantly, studies have shown  
that BAFMD may provide independent predictive data 
regarding future cardiovascular events.57,58  Endothelial 
dysfunction demonstrated by BAFMD, thus, may not 
only provide additional information regarding risk but 
also may provide a measure of atherogenic activity, a 
potential new therapeutic target. The panel for Preven- 
tion Conference V24 concluded that although assess- 
ments of endothelial function by BAFMD is a promis 
ing technique that may provide independent measures 
of CHD risk, additional prospective research and 
greater standardization of the measurement technique 
is needed before this modality can be included in rou 
tine clinical assessment of risk. 
Plaque characterization (MRI or CT imaging) 
Prevention Conference V24 briefly reviewed the util 
ity of MRI in evaluating plaque size and composition in 
the carotid arteries and aorta. Although it was noted 
that this technology had the potential for identifying 
unstable plaques, predicting future events, and evaluat 
ing responses to therapy, the panel felt that additional 
studies were needed to further clarify the potential of 
the new technology. 
Arterial elasticity 
Oliver and Webb59  recently reviewed methods for 
noninvasive assessment of arterial stiffness and their 
relationship to risk for atherosclerotic events. Measure 
ments of arterial stiffness were related not only to age 
but also to cardiovascular risk factors and to endothe 
lial function. Although the prognostic value of certain 
measurements, especially pulse wave velocity, seemed 
promising, these authors noted that these studies have 
generally been performed in small groups and with a 
limited number of at-risk subjects. As described in the 
current issue of the Journal, Cohn et al10 have mea- 
sured arterial elasticity by pulse counter analysis in a 
group of asymptomatic subjects as part of a screen for 
detection of early cardiovascular disease (preclinical 
diseases). Studies by this group have demonstrated 
that small and large arterial elasticity decreases with 
age, that small artery elasticity is significantly de 
creased in patients with cardiovascular disease, and 
that small arterial elasticity correlates with risk factors 
for coronary artery disease.60  Cohn et al10  hypothe- 
sized that a risk screen based on detection of early 
cardiovascular disease as measured by arterial elasticity 
and other disease markers rather than on standard risk 
factors will provide new information regarding risk 
and new targets for therapy. The proposed risk screen 
is to be validated by collecting data prospectively in a 
large group of subjects and relating the measurements 
to subsequent disease outcomes. 
Microalbuminuria 
A recent publication from the HOPE study61 evalu- 
ated the relationship between albuminuria and cardio- 
vascular events in individuals with and without diabe- 
tes. Microalbuminuria (defined as an albumin/ 
creatinine ratio [ACR] of >2 mg/umoL) occurred in 
32.6% of patients with diabetes and 14.8% of patients 
without. It was observed that any degree of albumin- 
uria was a risk factor for cardiovascular events in indi- 
viduals with and without diabetes. This risk increased 
progressively with increasing microalbuminuria. In 
fact, compared to the lowest quartile of microalbumin- 
uria, the relative risk for cardiovascular events in the 
fourth quartile was 1.97. Other studies have also docu- 
mented increased cardiovascular events associated 
with microalbuminuria.62
Assessment of silent ischemia 
A panel of Prevention Conference V63 reviewed the 
role of exercise electrocardiogram (ECG) testing, stress 
echo, exercise and pharmacological myocardial perfu- 
sion imaging, and positive emission tomography (PET) 
in assessing silent ischemia. It was noted that in the 
Multiple Risk Factor Interactive Trial (MRFIT),64 per- 
formed in middle-aged men, and in the Lipid Research 
Clinic Coronary Primary Prevention Trial,65 performed 
in asymptomatic men with hypercholesterolemia,  
there was a 4-fold increase in 7-year mortality and a 
5.7-fold increase in 7.4-year mortality, respectively, in 
subjects with abnormal exercise ECGs. The panel rec- 
ommended that exercise ECGs not be routinely used in 
unselected asymptomatic populations before office 
screening. They concluded, however, that exercise 
ECG testing may provide useful risk information to 
guide aggressive therapies in asymptomatic men >40
years of age with one or more risk factors (intermedi 
ate risk subjects). It was also felt that there was insuffi- 
cient data in women and in the elderly age group (age 
>75 years) to make recommendations regarding exer
cise ECG testing in these populations. Although a 
stress echo and myocardial perfusion imaging are com 
monly used (with PET less commonly used) to evalu 
ate chest pain symptoms or ischemia, the panel felt 
that these modalities did not significantly add to exer 
cise ECG testing in the middleaged, asymptomatic male 
population. It was felt these technologies may, 
however, provide additional information in women 
and in the elderly. The panel acknowledged the lack 
of general availability and high expense of the PET 
technology. 
Assessing risk for coronary heart disease potential algorithm. 
Potential algorithm for incorporating 
predisposing and conditional risk 
factors and assessments of preclinical 
vascular disease and atherosclerotic 
plaque burden into a risk assessment 
model 
It is certainly not appropriate or cost effective to 
utilize all of the potential factors listed in Table I for 
risk stratification in each patient. Figure 1 provides a 
potential algorithm to be considered for global risk 
assessment. This is modified from recommendations by 
AHA/ACC Scientific Statement9 and Prevention Confer- 
ence V.6 As outlined in the algorithm, the initial step 
in risk assessment is to screen for traditional Framing- 
ham risk factors and to calculate a 10-year Framingham 
risk score. A 10-year risk of <10% is classified as low
risk, 10% to 20% intermediate risk, and >20% as high
risk. 
Patients at low risk may require no further risk as- 
sessment, with the primary treatment being therapeu- 
tic lifestyle changes and medical therapies for selective 
risk factors that exceed guidelines (LDL, HTN). Pa- 
tients at high risk require aggressive medical and thera- 
peutic lifestyle changes without requiring additional 
risk stratification. Additional assessment may be consid- 
ered in the high-risk patient (ie, measurement of ho- 
mocysteine and/or small, dense LDL particles to iden- 
Figure 1 
tify an additional therapeutic target). Patients who are 
at an intermediate risk are candidates for further risk 
stratification as outlined in the algorithm. 
The AHA/ACC Scientific Statement on assessment of 
cardiovascular risk9 emphasized several factors to be 
considered in utilizing the Framingham score. The 
panel noted that although Framingham scoring does 
not directly measure long-term risk (>10 years), long- 
term risk could be approximated by summing risk 
score over successive age categories so that a 20-year 
risk may be twice the 10-year risk. Because the objec- 
tive or primary prevention is to reduce long-term as 
well as short-term risk, a patient in the 50 to 55 years 
age range who has a 15% 10-year risk may have a 
>30% risk for developing CHD before age 75 and thus
has a high long-term risk requiring more aggressive 
therapy. The panel emphasized that all major risk fac- 
tors should be treated regardless of short-term risk be- 
cause they may cause premature CHD over a period of 
many years. The panel emphasized that modification of 
lifestyle habits was the centerpiece of long-term risk 
reduction therapy, with the use of medical therapies 
as needed for hypertension and lipid disorders. As pre- 
viously discussed, patients with diabetes mellitus, 
symptomatic carotid artery disease, or peripheral vas- 
cular disease have CHD-equivalent risk and thus should 
be placed in the high-risk category as outlined in the 
algorithm. They do not require additional risk stratifica- 
tion to initiate aggressive medical therapy and thera- 
peutic lifestyle changes. In subjects who continue in 
intermediate risk, the presence of a strong family his- 
tory of premature CHD, criteria for metabolic syn- 
drome or insulin resistance, sedentary lifestyle or sig- 
nificant depression support moving the patient to the 
high-risk group. In subjects who then remain in the 
intermediate group, one or more conditional or emerg- 
ing risk factors may be evaluated for further risk strati- 
fication. As noted previously, each of these emerging 
risk factors has been identified in certain studies to 
provide independent relative risk for developing symp- 
tomatic coronary heart disease. We suggest that a pa- 
tient at intermediate risk may be moved to the high- 
risk category when the relative risk of a given 
emerging risk factor exceeds 2. As noted previously,20
an hs-CRP >3.0 mg/L is associated with a relative risk
>2 and thus may be sufficient to increase the patient
from intermediate to high risk. On the other hand, it 
may be reasonable to consider a cumulative relative 
risk provided by multiple risk factors that are moder- 
ately increased (ie, hs-CRP, homocysteine, lipoprotein 
(a), and fibrinogen to achieve a high-risk status). 
In the absence of predisposing or conditional risk 
factors, the subject at intermediate risk may be further 
risk stratified by measuring atherosclerotic plaque bur- 
den or other markers of preclinical disease. The most 
frequently used analyses at this time include coronary 
calcification score by EBCT or helical CT and measure- 
ment of the carotid IMT by B-mode echocardiography. 
As summarized previously, subjects who have coro- 
nary calcification scores placing them in the 75th per- 
centile or above for age may be considered patients 
who have accelerated plaque formation and may be 
considered at higher risk for future events. A coronary 
calcium scan of >400 places patients at any age above
the 75th percentile, indicating extensive plaque bur- 
den and the need for further functional testing for 
ischemia. Carotid IMT measures in the higher quartiles 
have been demonstrated to increase risk and may be 
used for further risk stratification.41 At the present  
time it is unclear whether certain noninvasive assess- 
ments of preclinical disease should be moved higher in 
the assessment algorithm. For example, a measurement 
of ABI should be a part of the baseline office physical 
exam in patients at intermediate or high risk. The pres- 
ence of an ABI <0.90 confirms the diagnosis of pe- 
ripheral vascular disease, a coronary disease equiva- 
lent.29,30  As suggested in the algorithm, the absence of 
CHD equivalents, predisposing and conditional risk 
factor and preclinical disease markers, with a low 
plaque burden may justify movement of a subject from 
intermediate to low risk. Although exercise studies and 
functional tests for silent ischemia may provide signifi- 
cant predictive information in the intermediate pa- 
tient,63,65  it has been placed last in the algorithm since 
positive tests are late manifestations of CHD occurring 
with hemodynamically significant coronary stenosis. A 
low coronary calcium score may preclude the need for 
further testing for silent ischemia. 
Development of a comprehensive 
global risk assessment model 
A goal at this time is to develop a comprehensive 
and cost effective risk stratification model that incor- 
porates Framingham risk factors with predisposing and 
emerging risk factors and noninvasive assessment of 
preclinical atherosclerosis. As noted, many of the non- 
Framingham risk factors provide relative risk informa- 
tion independent of the Framingham risk score. The 
Framingham risk score was derived from analysis of a 
single data set, whereas the enclosed list of non-Fram- 
ingham risk factors was obtained from multiple data 
sets (Table I). The challenge at this time is to develop 
global models that combine multiple risk factor vari- 
ables from multiple data sets. This model may then be 
used not only to define risk beyond that provided by 
the Framingham scoring system, but may also charac- 
terize risk that is modifiable by medical and lifestyle 
therapies and allow the efficacy of these therapies on 
risk and clinical outcomes to be determined. Validation 
of global risk stratification models requires the collec- 
tion of a large data set and documentation of disease 
outcomes over time. Additionally, these models will 
need to be validated and refined as sufficient outcomes 
accumulate and cost effectiveness is considered. 
Hu and Root66,67 have attempted to address this is- 
sue using an analysis that combines information from 
multiple data sources to create multivariable risk mod- 
els. This new approach involves building multivariable 
predictive models one variable at a time and adjusting 
for the colinearity and concordance between variables 
from different databases. A multivariable risk model 
has been developed by this group for CHD starting 
with the Framingham risk model, and then adding in a 
stepwise fashion a limited number of well-documented 
predisposing and conditional risk factors (Table I). 
These include family history, hs-CRP, lipoprotein (a), 
physical activity, homocysteine, fibrinogen, and oth- 
ers.66,67  Univariate relative risks are determined from a 
comprehensive review of prior epidemiologic studies 
for each of these new factors. Colinearity between the 
factors is estimated and adjusted for by using a large 
cross-sectional database of Americans (the NHANES III 
database). This model has the flexibility to be updated 
as new reports are published and variables can be 
added from the other risk factor categories, including 
coronary disease equivalents, emerging risk factors, 
and noninvasive assessment of atherosclerotic plaque 
burden, as appropriate. 
This technique is a first attempt to meet the need for 
an evidence-based, flexible, statistical method for risk 
assessment that can be used in the clinical environ- 
ment. Validation of this method has been difficult, 
given the constantly evolving list of potential biomark- 
ers and functional tests. To date, these investigators 
have used 2 initial approaches to validation. The me- 
chanics of the method have been evaluated using a 
single data set for creating and testing the model. A 
comparison of this new model with an empirical data 
driven method demonstrated a high correlation, R2, of 
approximately 99%. The more rigorous challenge for 
any model is to create it using one data set and vali- 
date it in another. This has been done in a limited sce- 
nario by adding these relatively weak variables avail- 
able from NHANESIII to the Framingham risk model 
and testing mortality outcomes in NHANES I. With 
these limited additions, the area under the ROC curve 
increased by a marginally statistical amount. More 
complete validations of this second type are ongoing. 
This kind of model also provides the flexibility for 
tracking the response to therapy (ie, risk reduction). 
For example, a therapeutic target for a specific modifi- 
able risk factor (eg, LDL <130 mg/dL) can be entered
into the risk equation and the alterable risk calculated 
and subsequently monitored. A patient may have a 
23% risk of heart disease in the next 10 years, but by 
lowering total cholesterol to <180 mg/dL, blood pres- 
sure to <120/80 mm Hg, and homocysteine to <7
µmol/L, the patient’s risk could be lowered to 5% risk
in 10 years. 
The information gathered in Table I and used in the 
proposed algorithm described in Figure 1 attempts to 
answer essentially 2 questions: (1) what is the pa- 
tient’s risk of CHD and (2) what are the therapeutic 
targets? There is a pressing need for a uniform and 
integrated risk stratification framework to guide the 
intensity and focus of risk reduction therapies in an 
evolving assessment process. 
The algorithm that we have proposed, based on rec- 
ommendations from the AHA/ACC Scientific State- 
ment,9 the AHA sponsored Prevention Conference V,6
the analyses by Hu and Root,66,67  and the risk models 
proposed by Cohn et al,10  will attempt to address this 
need. These methods for risk assessment and stratifica- 
tion will need further validation by acquisition of a 
large data set, cost-effectiveness considerations, and 
relating new risk models to disease outcomes over 
time. 
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